Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AMA Urges Government To Slash GP Red Tape, Australia
Slashing red tape would allow Australia"s General Practitioners to spend more time caring for patients, AMA President, Dr Andrew Pesce, said today.

A Growing Number Of Brits Cross The Atlantic For Donor Egg IVF Treatment At Shady Grove Fertility Center
More and more couples from the United Kingdom are crossing the ocean for donor egg treatment at Shady Grove Fertility Center, the Washington/Baltimore area"s largest in vitro fertilization (IVF) and fertility clinic. More than five dozen British patients received IVF treatment there last year, which was a 350-percent increase over 2007; most were donor egg recipients.
News of the day
IQ Explains Some Of The Difference In Heart Disease Between People Of High And Low Socio-economic Status
A unique study looking at the difference in cardiovascular disease (heart disease and stroke) and life expectancy between people of high and low socio-economic status has found that a person"s IQ may have a role to play.
Public Health

InteKrin Therapeutics To Present At The 2009 American Diabetes Association Annual Meeting

InteKrin Therapeutics, Inc. announced it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT. Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes." About INT131 INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively). About InteKrin InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin"s business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin"s team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders. InteKrin Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009